MedTrace Logo

The Safety, Tolerability and Pharmacokinetic Study of RAY1225

NCT05835752 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2026-03-05

No results posted yet for this study

Summary

This trial is conducted in China. The aim of the trial is to investigate safety, tolerability, pharmacokinetics and pharmacodynamics of RAY1225

Conditions

Interventions

DRUG

RAY1225

Administered SC

DRUG

Placebo

Administered SC

DRUG

RAY1225

Administered SC

DRUG

Placebo

Administered SC

DRUG

RAY1225

Administered SC

DRUG

Placebo

Administered SC

Sponsors & Collaborators

  • Guangdong Raynovent Biotech Co., Ltd

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-18
Primary Completion
2024-03-01
Completion
2024-03-23

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05835752 on ClinicalTrials.gov